when will eli lilly release retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Eli Lilly's retatrutide cuts weight

A Doctors Perspective As a physician with nearly two decades of experience prescribing these medications, heres my balanced take on who should consider GLP-1 treatment: Ideal Candidates: The Persistent Struggler : Youve consistently eaten well and exercised but still cant lose weight The Metabolic Challenger : You have insulin resistance, pre-diabetes, or metabolic syndrome The Health-Focused : Your weight is causing health issues like joint pain, sleep apnea, or high blood pressure The Committed Planner : Youre ready to combine medication with nutrition, exercise, and lifestyle changes Important Considerations: Results Potential : These medications can deliver weight loss comparable to bariatric surgery for many patients

The Evolution of Peptide Therapy Peptides leverage the bodys innate ability to heal and improve itself

Further research is warranted to establish comprehensive guidelines on UA supplementation tailored to specific health and performance goals

Long-term DSIP safety has not been established through clinical trials